Ting Xu

Ting Xu

Company: Alphamab Oncology

Job title: Chairman, Chief Executive Offier, Executive Director & Founder


Panel Discussion – Clinical Program Development Takeaways: How Can Researchers & Drug Developers in Any Targeted, Immune, Chemo, ADC Therapies Unite & Collaborate Future Directions to Optimize Our Own Drugs & Overall Patient Outlook? 11:30 am

Learnings from the past, how have we each developed our drugs considering previous work published? How can we optimize our program for any of the GI Cancer Indications? Thoughts on translating an established candidate from another solid tumor into GI cancer Utilizing patient groups, precision oncology & early detection in our clinical programsRead more

day: Day Two

Development of KN046, a PD-L1/CTLA-4 Bispecific, for Pancreatic Cancer 4:00 pm

Design of KN046 to reduce on target toxicity Dual ICI blocking demonstrated Significant anti-tumor activity with acceptable safety profile Early but promising sign of clinical activity in 1st pancreatic cancer seen in phase II trialRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.